I-Mab to Report Mid-Year 2023 Financial Results, Business and Corporate Updates on August 17, 2023
ROCKVILLE, Md. and
I-Mab Conference Call Information
Investors and analysts are invited to join the conference call at 8:00 a.m. EST on August 17 via Zoom:
Link: https://i-mabbiopharma.zoom.us/j/87349766033?pwd=bFhVejFDS1dHeWw3eklaeW1JcFhpUT09
Meeting ID: 873 4976 6033
Password: 194422
About I-Mab
I-Mab (Nasdaq: IMAB) is a global biopharmaceutical company exclusively focused on bringing transformational medicines to patients around the world through the discovery, development, and potential commercialization of novel or highly differentiated immunotherapies and biologics for oncology. I-Mab's innovative pipeline, including five key clinical assets and a pipeline of early-stage clinical and pre-clinical stage drug candidates are driven by the internal R&D's Fast-to-Proof-of-Concept and Fast-to-Market development strategies and through global partnerships. For more information, please visit http://www.i-mabbiopharma.com and follow us on LinkedIn, Twitter, and WeChat.
I-Mab Contacts
|
|
Richard Yeh Chief Operating Officer, interim Chief Financial Officer | Gigi Feng Chief Communications Officer |
View original content to download multimedia:https://www.prnewswire.com/news-releases/i-mab-to-report-mid-year-2023-financial-results-business-and-corporate-updates-on-august-17-2023-301895502.html
SOURCE I-Mab